Abiopharma

🔍 Atkins Susan E. (Director)

Company: BioXcel Therapeutics, Inc. (BTAI)

Report Date: 2026-08-12

Detailed Transactions and Holdings:

• Acquired 17,000 shares of Stock Option (Right to Buy) at $1.06 per share (Derivative)
  Date: 2026-08-12 | Code: A | Expires: 2036-08-12 | equity_swap_involved: 0 | shares_owned_after: 17,000.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The option vests and becomes exercisable as to 33% of the underlying shares on the first anniversary of the grant date, and the remaining shares vest in two equal annual installments thereafter on the second and third anniversary of the grant date, subject to the Reporting Person's continuous service with the Issuer through the relevant vesting dates.